Next year, the chairmanship of the Japan Pharmaceutical Manufacturers' Association is expected to change from current chair Miyabashira Asuka (宮柱明日香) to Chugai Pharmaceutical President Okuda Osamu (奥田修). This would mark the return of a Chugai Pharmaceutical executive to the chairmanship for the first time since the tenure of President Nagayama Osamu (永山治) from 1998 to 2004, according to reports.
Okuda Osamu (奥田修), president of Chugai Pharmaceutical, is expected to become the next chair of the Japan Pharmaceutical Manufacturers' Association, the industry association for domestic innovative drugmakers. The current chair is Miyabashira Asuka (宮柱明日香), formerly of Takeda Pharmaceutical Company, and is expected to complete her term in 2025.
Swiss pharmaceutical giant Roche owns more than 60% of Chugai Pharmaceutical, which is often regarded within the industry as a foreign-affiliated company. If an executive from Chugai Pharmaceutical returns to the chairmanship this time, it would be the first such case since President Nagayama Osamu (永山治), who served from 1998 to 2004.
The report notes that Chugai Pharmaceutical has market capitalisation exceeding ¥10 trillion and an operating margin above 50%, demonstrating strong profitability. The association's role includes representing domestic pharmaceutical manufacturers and conveying their requests to the Ministry of Health, Labour and Welfare.